Sarah Andres

Sarah Andres is a Research Fellow in the Department of Surgery at Memorial Sloan Kettering Cancer Center, actively contributing to the Gynecology Disease Management Team with cross-departmental collaborations in Medicine and Pathology and Laboratory Medicine. Her work bridges clinical practice and genomic research in women's cancers.

Her research program emphasizes gynecologic oncology through multiple interdisciplinary lenses: cancer genomics for molecular characterization of tumors, endometrial and ovarian cancer pathophysiology, molecular pathology for diagnostic refinement, and clinical trials of novel targeted therapies. She integrates genomic technologies with therapeutic development to address unmet needs in recurrent disease settings, particularly focusing on hormone receptor-positive malignancies.

Analysis of her 2024-2025 publications reveals a cohesive research trajectory centered on genomic characterization of aggressive gynecologic cancers (endometrial/uterine serous carcinomas) and innovative clinical trial designs. Key methodological approaches include whole-genome sequencing for tumor heterogeneity mapping and basket trials evaluating progesterone antagonists like onapristone. Thematic priorities encompass biomarker-driven therapy selection, neoadjuvant treatment optimization, and surgical innovation through imaging technologies.

No scientific awards were documented in the available institutional records.

While advising relationships and grant funding specifics were not disclosed in the source materials, her collaborative publication pattern indicates active mentorship within multidisciplinary research teams at MSKCC, particularly through the Gynecology Disease Management Team framework.

Dr. Andres operates within Memorial Sloan Kettering's integrated Gynecology Disease Management Team, a multidisciplinary unit within Surgery that coordinates clinical care, translational research, and therapeutic innovation for gynecologic cancer patients. This structure enables rapid translation of genomic findings like those in her serous carcinoma studies into clinical trial protocols such as the onapristone basket studies.